Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Award: Doctoral Foreign Study Award (DFSA)

Direct Payment

$105,000.00

Engineering the HIV-1 gp41 pocket to increase rigidity and enable small-molecule drug discovery

FY 2019-20

Summary
Since the start of the HIV/AIDS epidemic, over 77 million people have become infected with HIV and half of those infected have died of AIDS-related illnesses. The proposed research is focused on addressing the need for new classes of anti-HIV drugs that are resistant to the emergence of HIV-1 mutations. Gp41 is a HIV-1 surface protein that mediates fusion with host cells and contains a highly conserved cavity in its structure, referred to as the "gp41 pocket". Currently, there is only one drug that targets gp41 to inhibit viral entry into human cells. This peptide drug (T-20) has limited clinical utility because it has poor bioavailability and requires two daily injections. Literature reports indicate that efforts to identify a small-molecule drug against gp41 have hitherto been unsuccessful. A potential explanation for this is the observation that the gp41 pocket is highly malleable. Our hypothesis is that (1) it is more difficult to identify small-molecule drug leads for a target that is malleable compared to one that is rigid, and (2) a high-throughput screen (HTS) with a rigid target will yield better hit rates which will potentiate the discovery of a new small-molecule inhibitor of HIV-1 fusion. To test this hypothesis, the gp41 pocket will first be engineered to increase rigidity using protein engineering, and then the rigid pocket will be subjected to an HTS. An HTS will identify small-molecule chemicals, referred to as hits, that bind to the rigid gp41 pocket. By studying the binding mechanism of different hits to gp41 we hope to elucidate critical chemical interactions that are necessary for the design of a potent anti-HIV-1 drug. Since the gp41 pocket is highly conserved across HIV-1 strains, a drug that targets the pocket is likely to be resistant to the development of escape mutations. Thus, this research has the potential to improve the health of HIV infected individuals that develop resistance to the currently available antiretroviral medications.
Program
Doctoral Award: Doctoral Foreign Study Award (DFSA)
Location
California, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
415338
Name
Bruun Theodora U
Region
California
Country
United States of America
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Engineering the HIV-1 gp41 pocket to increase rigidity and enable small-molecule drug discovery
Programtype2
Studentship Programs
Orgnameinp2
Direct Payment
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award: Doctoral Foreign Study Award (DFSA)
Keyworddelim
Hiv-1 Fusion Inhibition; Protein Engineering; Small-Molecule Drug Discovery; Solid Phase-Peptide Synthesis; X-Ray Crystallography
Abstract
Since the start of the HIV/AIDS epidemic, over 77 million people have become infected with HIV and half of those infected have died of AIDS-related illnesses. The proposed research is focused on addressing the need for new classes of anti-HIV drugs that are resistant to the emergence of HIV-1 mutations. Gp41 is a HIV-1 surface protein that mediates fusion with host cells and contains a highly conserved cavity in its structure, referred to as the "gp41 pocket". Currently, there is only one drug that targets gp41 to inhibit viral entry into human cells. This peptide drug (T-20) has limited clinical utility because it has poor bioavailability and requires two daily injections. Literature reports indicate that efforts to identify a small-molecule drug against gp41 have hitherto been unsuccessful. A potential explanation for this is the observation that the gp41 pocket is highly malleable. Our hypothesis is that (1) it is more difficult to identify small-molecule drug leads for a target that is malleable compared to one that is rigid, and (2) a high-throughput screen (HTS) with a rigid target will yield better hit rates which will potentiate the discovery of a new small-molecule inhibitor of HIV-1 fusion. To test this hypothesis, the gp41 pocket will first be engineered to increase rigidity using protein engineering, and then the rigid pocket will be subjected to an HTS. An HTS will identify small-molecule chemicals, referred to as hits, that bind to the rigid gp41 pocket. By studying the binding mechanism of different hits to gp41 we hope to elucidate critical chemical interactions that are necessary for the design of a potent anti-HIV-1 drug. Since the gp41 pocket is highly conserved across HIV-1 strains, a drug that targets the pocket is likely to be resistant to the development of escape mutations. Thus, this research has the potential to improve the health of HIV infected individuals that develop resistance to the currently available antiretroviral medications.
Competitiondate
201910
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Bruun, Theodora U
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~
Direct Payment - $105,000 Grant (2019-20) | Canada Spends